Home > Focus Areas > DLBCL Connect > Post
4yr
WVU Cancer Institute Cellular Therapy Program doubles CAR-T offerings with two new treatments | WVU Medicine
MORGANTOWN, W.Va. - The WVU Cancer Institute Osborn Hematopoietic Malignancy and Cellular Therapy Program is offering two new forms of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of lymphoma. These additions double the offerings of the CAR-T therapy line offered by the Institute.
-
DLBCL Connect4yrThis development is notable because it provides increased access to rural populations in West Virginia. Could this be a developing trend to combat health disparities?
-
Naveed Saleh, MD, MS – Skipta Team4yrAn interesting aspect here is that increased healthcare access is provided in a rural community. Perhaps a trend towards combating healthcare disparities?
-
Mark Fesler4yrProbably the case for many centers around the country ...